Interventions for Cutaneous Disease in Systemic Lupus Erythematosus: Summary of a Cochrane Review.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 35019939.
- Also identified by DOI 10.1001/jamadermatol.2021.5485.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
What is the efficacy of interventions for cutaneous disease in systemic lupus erythematosus (SLE) in randomized clinical trials (RCTs)? Available RCT evidence on the management of cutaneous disease in SLE is sparse and of limited quality. Among traditional options, methotrexate and hydroxychloroquine have the strongest evidence compared with placebo in the end points of complete clinical response and number of clinical flares, respectively, while chloroquine appears noninferior to methotrexate in achieving complete clinical response.
Medical subject headings
- Lupus Erythematosus, Systemic
- Skin Diseases